viral
pathogen
commonli
isol
children
communityacquir
pneumonia
cap
virus
like
respiratori
syncyti
viru
human
rhinoviru
human
metapneumoviru
parainfluenza
virus
influenza
may
act
sole
pathogen
may
predispos
bacteri
pneumonia
varieti
mechan
new
emerg
reemerg
viral
pathogen
occasion
caus
outbreak
sever
respiratori
tract
infect
children
influenza
viru
pandem
result
increas
rate
influenzarel
hospit
death
children
rapid
viral
diagnost
test
base
antigen
detect
nucleic
acid
amplif
increasingli
avail
clinic
use
confirm
import
viral
infect
children
hospit
cap
recent
publish
guidelin
manag
cap
children
note
posit
viral
test
result
modifi
clinic
decis
make
children
suspect
pneumonia
allow
antibacteri
therapi
withheld
absenc
clinic
laboratori
radiograph
find
suggest
bacteri
coinfect
communityacquir
pneumonia
cap
lead
singl
caus
death
among
children
younger
year
old
worldwid
estim
million
death
among
million
episod
per
year
us
million
episod
per
year
hospit
among
immunocompet
children
cap
may
caus
wide
varieti
microb
includ
mani
virus
typic
bacteria
eg
streptococcu
pneumonia
atyp
bacteria
eg
mycoplasma
pneumonia
mycobacterium
tuberculosi
relat
speci
fungi
histoplasma
capsulatum
viral
infect
involv
episod
cap
children
year
old
older
children
virus
may
act
sole
pathogen
pediatr
cap
predispos
bacteri
pneumonia
viral
etiolog
vari
geographi
season
age
patient
studi
respiratori
syncyti
viru
rsv
human
rhinoviru
hrv
human
bocaviru
hbov
human
metapneumoviru
hmpv
parainfluenza
virus
piv
describ
consist
common
virus
associ
cap
children
coinfect
influenza
bacteri
pathogen
associ
develop
sever
diseas
sever
case
rsv
bronchiol
requir
mechan
ventil
often
bacteri
coinfect
develop
cap
caus
bacteri
pathogen
colon
upper
airway
may
facilit
viral
respiratori
tract
infect
damag
ciliat
respiratori
epithelium
interfer
normal
protect
mucociliari
clearanc
mechan
augment
adhes
bacteri
pathogen
respiratori
epitheli
cell
directli
diminish
effect
neutrophil
compon
innat
adapt
immun
allow
overgrowth
bacteria
nasal
passag
increas
likelihood
aspir
lower
respiratori
tract
andor
facilit
transloc
bacteria
upper
airway
across
mucos
barrier
bloodstream
secondari
bacterem
seed
lung
parenchyma
viral
lower
respiratori
tract
infect
may
gener
infiltr
evid
chest
radiograph
difficult
distinguish
episod
cap
due
typic
atyp
bacteri
agent
seem
especi
true
viral
etiolog
bronchiol
young
children
review
focus
recent
studi
provid
insight
variou
aspect
viral
infect
associ
subsequ
typic
bacteri
cap
includ
season
pandem
influenza
recent
studi
complic
cap
sever
recent
publish
studi
employ
sophist
molecular
diagnost
techniqu
ad
grow
bodi
data
regard
impact
viral
infect
children
cap
prospect
studi
children
hospit
radiograph
confirm
cap
one
finnish
hospit
januari
april
confirm
mix
bacterialvir
infect
common
expector
induc
sputum
sampl
obtain
children
month
year
age
test
six
bacteria
cultur
polymeras
chain
reaction
pcr
test
virus
antigen
detect
pcr
test
least
one
respiratori
pathogen
identifi
patient
bacteria
isol
sampl
virus
commonli
detect
viral
pathogen
hrv
hbov
hmpv
adenoviru
coronavirus
rsv
seventeen
patient
posit
two
virus
patient
three
virus
bacterialvir
coinfect
identifi
pneumoniaerhinoviru
frequent
combin
major
limit
studi
probabl
contamin
mani
bacteri
cultur
nasoor
oropharyng
flora
commonli
colon
nasal
passag
oropharynx
sometim
etiolog
pneumonia
ie
aureu
pneumonia
catarrhali
nontyp
h
influenza
investig
madrid
spain
studi
etiolog
presum
bacteri
cap
children
year
age
hospit
septemb
juli
cap
defin
presenc
consolid
andor
pleural
effus
chest
radiograph
nasopharyng
aspir
obtain
admiss
patient
test
respiratori
virus
rtpcr
least
one
viru
isol
patient
patient
two
virus
isol
rsv
identifi
frequent
follow
hrv
hbov
adenoviru
adv
piv
hmpv
influenza
identifi
patient
viru
detect
higher
infant
month
age
older
children
studi
vs
rsv
common
younger
children
hrv
influenza
common
older
children
virusposit
patient
like
virusneg
patient
present
hypoxia
wheez
length
hospit
stay
durat
oxygen
therapi
durat
fever
differ
among
cap
case
associ
rsv
hrv
hbov
hmpv
children
month
old
bacteri
etiolog
cap
confirm
posit
blood
cultur
case
yield
pneumonia
one
virus
isol
includ
four
influenza
rsv
recent
studi
shown
similar
viral
result
children
symptom
respiratori
tract
infect
sixcent
studi
south
africa
nasopharyng
oral
specimen
patient
sever
acut
respiratori
infect
evalu
multiplex
pcr
test
patient
children
physiciandiagnos
lower
respiratori
tract
infect
lrti
although
adult
includ
well
median
age
year
singl
viru
detect
dual
infect
hrv
detect
rsv
adv
enteroviru
piv
hmpv
influenza
b
strain
detect
hrv
rsv
adv
commonli
involv
coinfect
two
recent
studi
viral
infect
young
children
dispar
geograph
locat
combin
result
indic
moder
similar
epidemiolog
viral
respiratori
tract
infect
children
around
world
februari
februari
children
year
old
southeast
madagascar
fever
symptom
acut
respiratori
infect
neg
test
malaria
evalu
multiplex
pcr
virus
two
atyp
bacteri
agent
hrv
detect
hmpv
coronaviru
piv
rsv
influenza
adenoviru
hbov
pneumonia
c
pneumonia
detect
respect
coinfect
note
first
wave
pandem
influenza
spring
dalla
texa
singl
viru
infect
identifi
symptomat
children
hrv
piv
hmpv
pandem
isol
viru
respiratori
tract
alway
prove
activ
infect
children
may
shed
virus
prolong
period
viral
detect
may
simpli
repres
asymptomat
persist
nevertheless
studi
consist
other
demonstr
varieti
viral
etiolog
associ
lower
respiratori
tract
infect
often
alway
evid
concomit
bacteri
infect
influenza
viru
infect
long
associ
secondari
bacteri
cap
recent
publish
retrospect
cohort
studi
examin
impact
season
influenza
viru
infect
hospit
children
complic
pneumonia
requir
pleural
fluid
drainag
data
obtain
pediatr
health
inform
system
phi
databas
contain
resourc
util
data
freestand
children
hospit
state
district
columbia
januari
june
children
complic
pneumonia
underw
pleural
drainag
procedur
label
influenza
coinfect
cohort
aureu
common
bacteria
associ
influenza
coinfect
although
pneumonia
identifi
almost
often
multivari
analysi
influenza
coinfect
associ
higher
odd
intens
care
unit
admiss
need
mechan
ventil
vasoact
infus
well
longer
hospit
stay
data
suggest
viral
test
institut
appropri
isol
precaut
prudent
children
hospit
complic
cap
emphas
need
annual
influenza
immun
children
month
age
influenza
pandem
rate
hospit
due
laboratoryconfirm
influenza
substanti
higher
us
children
typic
season
influenza
viru
strain
circul
preced
year
mark
pandem
ratio
fiveand
sixfold
higher
respect
averag
preced
season
influenza
year
among
children
hospit
influenza
region
us
monitor
emerg
infect
program
cdc
underli
medic
condit
asthma
case
common
pneumonia
present
although
bacteri
coinfect
confirm
pneumonia
present
follow
aureu
pyogen
among
children
die
hospit
case
underli
medic
condit
hospit
pneumococc
pneumonia
increas
baselin
children
year
old
us
largest
rel
increas
among
age
group
second
wave
pandem
influenza
fall
denver
co
second
wave
peak
octob
case
invas
pneumococc
diseas
children
year
old
mostli
pneumonia
case
peak
preced
season
influenza
outbreak
februari
clear
whether
increas
case
number
octob
versu
februari
stabl
background
popul
reflect
increas
attack
rate
influenza
pandem
enhanc
facilit
develop
pneumococc
pneumonia
pandem
versu
season
strain
multicent
studi
children
hospit
pandem
influenza
canadian
pediatr
hospit
impact
network
found
asthma
common
among
children
hospit
season
influenza
strain
preced
year
vs
p
headach
cough
gastrointestin
symptom
common
pandem
cohort
compar
prior
year
well
radiolog
confirm
pneumonia
occur
hospit
children
pandem
influenza
requir
intens
care
compar
season
influenza
preced
year
p
specif
coinfect
data
provid
studi
among
children
hospit
pandem
influenza
multipl
belgian
center
radiograph
evid
pneumonia
pneumococc
coinfect
confirm
children
posit
blood
cultur
similar
seri
children
admit
four
thai
hospit
infiltr
chest
radiograph
present
among
infant
month
old
hospit
texa
laboratoryconfirm
pandem
influenza
diagnos
bacteri
coinfect
admiss
bacteri
pneumonia
present
urinari
tract
infect
anoth
infant
develop
ventilatorassoci
pneumonia
due
pseudomona
aeruginosa
cluster
sever
lower
respiratori
tract
infect
cap
may
associ
novel
emerg
uncommonli
seen
pathogen
recent
exampl
includ
sever
acut
respiratori
syndrom
sar
coronaviru
outbreak
human
coronaviru
hbov
first
identifi
precis
role
respiratori
pathogen
remain
unconfirm
august
septemb
increas
pediatr
admiss
lower
respiratori
tract
ill
recogn
commun
hospit
rural
arizona
time
pediatr
admiss
respiratori
ill
compar
mean
time
period
previou
year
eighteen
patient
similar
ill
character
cough
tachypnea
hypoxemia
new
onset
wheez
common
routin
studi
conduct
arizona
depart
health
servic
fail
identifi
pathogen
seven
nasopharyng
sampl
refer
center
diseas
control
prevent
cdc
test
specimen
five
children
test
posit
human
enteroviru
one
also
evid
pneumococc
infect
first
identifi
four
children
bronchiol
pneumonia
subsequ
rare
identifi
caus
acut
respiratori
tract
infect
children
spectrum
clinic
manifest
caus
requir
studi
known
appear
similar
member
picornavirida
famili
eg
rhinovirus
enterovirus
like
enterovirus
caus
central
nervou
system
diseas
like
hrv
infect
may
result
mild
upper
respiratori
tract
infect
recent
cluster
ill
like
one
arizona
confirm
viru
caus
sever
even
fatal
pneumonia
children
commerci
avail
molecular
diagnost
test
system
may
abl
distinguish
hrv
pediatr
hospit
philadelphia
identifi
unusu
larg
number
children
hrv
infect
children
test
posit
hrv
august
octob
hrv
recov
twice
proport
sampl
time
period
previou
year
number
patient
sicker
typic
expect
hrv
infect
twentyeight
sampl
refer
cdc
yield
half
patient
infect
year
age
although
none
die
requir
admiss
icu
median
durat
hospit
day
last
half
novel
swine
influenza
variant
label
identifi
children
us
lowlevel
humantohuman
transmiss
may
occur
although
widespread
circul
note
yet
strain
appear
close
relat
influenza
variant
circul
recent
seropreval
studi
canada
show
mani
adolesc
young
adult
children
year
adult
year
old
antibodi
crossreact
strain
emerg
suggest
new
influenza
strain
emerg
global
substanti
need
ongo
influenza
surveil
global
annual
death
pneumonia
children
less
year
old
decreas
like
due
combin
factor
includ
advanc
health
care
deliveri
avail
support
care
antimicrobi
agent
well
increas
avail
vaccin
prevent
h
influenza
type
b
mani
pneumococc
infect
still
much
work
left
done
worldwid
prevent
access
care
us
hospit
pneumonia
decreas
follow
introduct
conjug
pneumococc
vaccin
preval
pleural
empyema
complic
pneumonia
increas
twofold
case
per
children
aureusassoci
empyema
increas
time
period
fortun
outcom
pleural
empyema
appropri
manag
excel
within
month
present
pleural
empyema
clinic
signific
longterm
sequela
cohort
children
manag
singl
center
toronto
analysi
data
hospit
nonsever
cap
us
children
hospit
particip
phi
show
substanti
variat
manag
among
hospit
median
age
year
children
year
age
median
length
stay
lo
day
hospit
median
lo
day
shorter
lo
correl
rate
return
emerg
depart
within
day
discharg
major
children
cap
hospit
chest
radiographi
interquartil
rang
complet
blood
count
interquartil
rang
blood
cultur
obtain
half
interquartil
rang
interquartil
rang
virolog
test
creactiv
protein
concentr
respect
children
cap
studi
period
receiv
cephalosporin
either
alon
combin
macrolid
vancomycin
clindamycin
recent
publish
clinic
practic
guidelin
pediatr
cap
recommend
ampicillin
penicillin
g
treatment
children
us
hospit
uncompl
cap
fulli
immun
live
area
lack
highlevel
penicillin
resist
among
invas
pneumococci
lowresourc
antimicrobi
stewardship
program
use
welldissemin
institut
guidelin
coupl
educ
outreach
highli
visibl
infecti
diseas
clinician
prove
success
increas
ampicillin
decreas
ceftriaxon
use
uncompl
cap
children
rapid
viral
diagnost
test
base
antigen
detect
nucleic
acid
amplif
increasingli
avail
clinic
use
expand
array
pathogen
multiplex
pcr
test
increas
proport
children
cap
viral
infect
identifi
one
multiplex
test
virus
pneumonia
bordetella
pertussi
fulli
autom
use
selfcontain
pouch
process
within
hour
current
avail
us
pediatr
cap
guidelin
note
posit
viral
test
result
modifi
clinic
decis
make
children
suspect
pneumonia
allow
antibacteri
therapi
withheld
absenc
clinic
laboratori
radiograph
find
suggest
bacteri
coinfect
grow
evid
risk
seriou
bacteri
infect
low
children
laboratoryconfirm
viral
infect
may
true
especi
infant
young
children
test
posit
influenza
rsv
piv
adv
indic
antimicrobi
therapi
howev
posit
rapid
viral
test
justif
withhold
antimicrobi
therapi
infant
children
appear
sever
ill
eg
respiratori
failur
evid
bacteri
coinfect
even
rapid
viral
test
posit
vast
major
children
develop
cap
recov
fulli
even
sever
bacteri
coinfect
provid
manag
appropri
abnorm
pulmonari
function
test
may
persist
month
year
rsv
viral
lrti
infant
young
children
whether
symptomat
lrti
simpli
predictor
versu
etiolog
subsequ
abnorm
remain
unclear
viral
lrti
especi
adv
measl
may
associ
complic
bronchiol
obliteran
bronchiectasi
wide
rang
viral
infect
children
involv
lower
respiratori
tract
mimic
bacteri
cap
facilit
develop
diagnosi
bacteri
etiolog
cap
remain
problemat
children
especi
among
young
children
induc
sputum
cultur
suffici
diagnost
qualiti
difficult
obtain
due
difficulti
distinguish
viral
bacteri
etiolog
cap
especi
young
children
antibiot
often
overprescrib
viral
lrti
recent
develop
rapid
diagnost
test
short
process
time
may
permit
judici
use
antimicrobi
agent
children
appar
cap
us
greater
standard
care
children
cap
reason
expect
may
facilit
clinic
practic
guidelin
criteria
hospit
discharg
transit
intraven
oral
therapi
use
viral
bacteri
diagnost
test
manag
decis
need
develop
improv
vaccin
influenza
viral
infect
remain
prioriti
increas
global
avail
exist
vaccin
measl
haemophilu
influenza
type
b
pneumococci
vigil
emerg
viral
infect
includ
new
influenza
variant
maintain
develop
new
antivir
agent
novel
mechan
action
need
current
exampl
act
level
host
rather
microb
blockad
influenza
viru
bind
sialic
acid
residu
respiratori
epitheli
cell
next
decad
climat
chang
environment
air
pollut
urban
area
econom
polit
upheav
may
impact
populationlevel
nutrit
health
access
health
care
potenti
season
epidemiolog
aspect
respiratori
virus
may
becom
import
factor
regard
cap
infect
children
potenti
new
virus
emerg
becom
human
pathogen
may
increas
cluster
unexplain
respiratori
ill
alway
report
appropri
public
health
agenc
disclosur
dr
c
wood
serv
chair
data
safeti
monitor
board
pediatr
studi
new
antibiot
ceftarolin
cerexa
receiv
research
grant
fund
pfizer
